Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod in Pediatric Crohn's Disease
NCT05470985Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of ozanimod in Crohn's disease, sponsored by Bristol Myers Squibb. Started Aug 2023; status: terminated.
02
Drugs
ozanimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05470985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470985.